“The consequences of neurological disease affects so much more than the nervous system; it often turns the affected person’s life upside down. This feeds our relentless quest for ‘what’s next’ in innovative treatments”
Dieter Schultewolter, VP Global Medical Affairs Neuroscience
Did you know that one third of the world lives with a neurological condition, making it one of the leading causes of illness and disability worldwide?
A neurological condition is defined as any condition that affects the brain, spinal cord and/or nerves. Because these systems control the mind and body, neurological conditions affect the way people think, feel and interact with the world. They include conditions which have an impact on mental health, such as schizophrenia and dementia, as well as movement disorders – which may also have a psychological impact - including Parkinson’s Disease (PD), multiple sclerosis (MS), Tardive Dyskinesia (TD) and Huntington’s Disease (HD).
As well as affecting patients directly, neurological conditions often also carry secondary risks. 78% of patients have a higher risk of cardiovascular disease (CVD) and a 85% higher risk of dying from CVD, while schizophrenia patients have 15-20 years’ reduced life expectancy.
In addition, they can carry a high psycho-social burden that may amplify the physical effects, as outlined below. And these conditions may also severely disrupt the lives of the patient’s family and friends.
Teva’s commitment to supporting patients with neurological conditions stretches back over 30 years, when we first developed treatments for MS and PD. Since then, our widening neuroscience portfolio includes innovative treatments that are supporting patients across schizophrenia, MS, migraine, TD and HD. Today we have seven medicines for neurological conditions in our pipeline and 3,700 employees working in six R&D hubs in the US, Israel, India, Croatia, the UK and Australia.
However, it’s not just about providing investigational medicines, though this is very important. It’s also about using cutting-edge technology, such as artificial intelligence (AI), to speed up the development of medicines and diagnoses. For example, Teva is investigating the use of facial recognition tools for the diagnosis of TD patients, and automated speech-based tools for the prediction of a potential clinical deterioration of patients with schizophrenia.
We are also using advanced technologies to improve efficiency in everything from collecting patient information to developing medication and advancing patient care; for example, improving efficiency in clinical trial site selection can amplify development programs, reducing the wait for new medication for conditions with high unmet medical need.
These advancements reinforce neuroscience as a priority for Teva—central to its Pivot to Growth strategy and its purpose: We are All in for Better Health.
How seriously we take “We are all in for better health” is illustrated by Teva’s leaders in this area, all experts in their fields, marrying significant clinical and industry experience. They have a very deep and direct knowledge of the life-changing effects neurological conditions have on patients, family and friends.
Psychiatrist and psychotherapist Dieter Schultewolter leads the Global Medical Affairs team in neuroscience and brings over 30 years’ experience to the role, working as both a medical doctor and industry professional. “There is a very high unmet medical need in neuroscience, along with great suffering,” he explains.
“Patients often put up with a lot of misunderstanding and stigma in their lives. They become extremely isolated and very lonely. We want to do something about that.”
- Dieter Schultewolter, VP Global Medical Affairs Neuroscience, Teva Pharmaceuticals
Mark Suett is a Senior Director on the Medical Affairs team, leading on neuropsychiatry, with wide-ranging experience of treating patients with schizophrenia from 15-years working as a psychiatrist. He outlines the challenges in providing treatment for the condition.
“People living with schizophrenia often have limited awareness of their illness and because of that, taking oral medication, potentially for the rest of their lives, is a challenge. Subsequently, adherence rates for all schizophrenia treatments are poor.”
To answer this challenge, Teva is working to improve how treatments are delivered - for example, introducing long-acting injections that can be taken every month, instead of a daily tablet.
“We are looking at things from the patients’ perspective, looking at the challenges and how we help people overcome them.” ~ Mark Suett, Senior Director, Teva Medical Affairs
Verena Ramirez Campos is a Senior Global Medical Director in Neurology and has extensive knowledge of neurological conditions including TD and HD from her time working as a neurologist and immunologist.
“Both TD and HD can carry a high burden for patients,” she says. “TD is characterized by a predominantly involuntary facial movement and is often experienced by patients who have used anti-psychotic drugs, so there is frequently an underlying mental health condition. Physical complications include tooth fractures and problems with speech and swallowing, and the condition can also generate a lot of stigma, which may lead to isolation and depression.”
The situation is similar for HD, an inherited disorder that causes chorea, involuntary movements affecting the body’s muscles that impacts patients physically, psychologically, functionally and socially.
For patients like Zion, chronic movement disorders can take away the ability to do the things we all take for granted, simple things like holding a spoon.
Once a man who worked with his hands as a carpenter and photographer, Zion's progressive illness meant he had to be fed through a tube - until a treatment gave him back some control of his movement, helping him swallow easier and hold a spoon to eat unaided.
Once a man who worked with his hands as a carpenter and photographer, Zion's progressive illness meant he had to be fed through a tube - until a treatment gave him back some control of his movement, helping him swallow easier and hold a spoon to eat unaided.
Conditions like pediatric migraine and rare diseases are part of our focus
which affects around 9% of children
in Multiple System Atrophy (MSA) and Parkinson's Disease
and education to drive progress
Verena also works in the area of migraine, which is estimated to affect more than 10% of the global population. Again, it’s not just about treating the physical pain aspect, it’s also about acknowledging the connected range of symptoms suffered by patients, from light and noise phobias to nausea and vomiting, which leads to reduced quality of life between episodes.
“The hardest thing with having a chronic migraine condition is not being able to control things in your life,” says Daisy Swaffer. “I used to have a really good career in IT, working with people that I loved. Eventually, I had to stop working. It's so frustrating. I'd loved my job, and I can't do it anymore because the migraines physically stop me from doing it.” See Daisy’s story.
Recognizing that the pediatric population living with migraine is an underserved population that needs a treatment solution, Teva is also working on new treatments for pediatric migraine, a condition that affects approximately 9% of children and adolescents worldwide.
Teva’s commitment to addressing areas of high unmet medical need in neuroscience is further exemplified by our clinical development program focused on Multiple System Atrophy (MSA), a rare disease for which treatments are not currently available, as well as our exploration of innovative treatments for PD, informed by the latest scientific advancements.
Collaboration and education are also key parts of Teva’s work in the field of neuroscience, generating and sharing data, knowledge and experience. All our endeavours are driven by one purpose, to help support patients and the people who care for them.
“The most rewarding thing is seeing my work helping to shape understanding of how we treat patients successfully. I don’t work as a physician anymore but I’m proud to be one of the people providing the tools to help.”
~ Verena Ramirez Campos, Senior Global Medical Director in Neurology at Teva
Teva acknowledges that it is both a privilege and obligation to support fellow human beings living with chronic conditions – we are proud to continue our work.
30+ Years of Commitment: Teva's Longstanding Role in Neuroscience
7 medicines in our pipeline |
Treatments for schizophrenia, MS, migraine, TD and HD. |
![]() |
1 in 3 people live with neurological condition, affecting how we think, feel, move and connect.
3700+ employees working with 6 global R&D hubs |
Using AI for faster diagnosis and drug development |
![]() |
![]() |
These advencements make neuroscience central to Teva's strategy and purpose. We are all in for better health.
NPS-ALL-NP-01532-APR-2025